Stockscreener 앱 받기
244.96
0.36%
-0.89
시장 영업 전:
244.78
-0.18
-0.07%
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Understanding HER2 Expression in Gastroesophageal AdenocarcinomaJazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion - AKM.RU
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed - simplywall.st
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout (JAZZ) - Seeking Alpha
Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
JAZZ Maintained by Morgan Stanley -- Price Target Raised to $283 - GuruFocus
Jazz Pharmaceuticals (JAZZ) Acquires Actio Biosciences for $820 Million - GuruFocus
Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says - marketscreener.com
Morgan Stanley Adjusts Jazz Pharmaceuticals PT to $283 From $280, Maintains Overweight Rating - marketscreener.com
Jazz Pharmaceuticals buys Actio for up to $1.3bn - BioXconomy
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront - Pharmaceutical Technology
Jazz Pharmaceuticals (JAZZ) Short Interest & Short Float | Updated Aug 2026 $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript - The Globe and Mail
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Jazz Pharmaceuticals to Acquire Actio Biosciences in Merger - TipRanks
Jazz Pharmaceuticals (JAZZ) plans $820M Actio Biosciences deal plus $500M milestones - Stock Titan
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M - Investing.com India
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Solid Earnings Are Supported By Other Strong Factors - 富途牛牛
Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push - Law360
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal - BioPharma Dive
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - Reuters
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline - BioSpace
JAZZ Looks 70.7% Overvalued on GF Value™ Amid $820M Actio Biosci - GuruFocus
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Jazz Pharmaceuticals to Acquire Actio Biosciences in Deal Worth Up to $1.32 Billion - citybiz
JAZZ Looks 68.7% Overvalued on GF Value™ After Actio Biosciences Acquisition - GuruFocus
Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio - TipRanks
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M By Investing.com - Investing.com Australia
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, gaining a new epilepsy drug ABS-1230. - Pluang
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio - PR Newswire
Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ): Investor Outlook on a Biotech Powerhouse with a 9.51% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jazz Pharmaceuticals plc 2026 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) 2026-08-07 - Seeking Alpha
Jazz Pharmaceuticals plc SEC Filing (Aug 7, 2026) - Stock Titan
Jazz Pharmaceuticals plc (JAZZ) News, Articles, Events & Latest Updates - Stocktwits
JAZZ vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
FMR LLC and Abigail Johnson disclose 7.4% Jazz Pharmaceuticals (JAZZ) ownership - Stock Titan
Jazz Pharmaceuticals (JAZZ) Director Bruce Cozadd Sells 6,000 Sh - GuruFocus
Jazz Pharmaceuticals Plc Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next - Moomoo
What Does Jazz Pharmaceuticals (JAZZ) Raised Guidance Mean With FDA Decisions Ahead? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Stock May Stay Below Fair Value Following Raised Guidance - simplywall.st
Jazz Pharmaceuticals' Re-Rating Story Has Legs (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Bank of America Corp DE - marketbeat.com
Amundi Acquires 53,454 Shares of Jazz Pharmaceuticals PLC $JAZZ - marketbeat.com
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,517,880.00 in Stock - MarketBeat
Jazz Pharmaceuticals stock hits all-time high at 261.46 USD - Investing.com
JAZZ PHARMACEUTICALS PLC : PIPER SANDLER RAISES TARGET PRICE TO $310 FROM $301 - webull.com
Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push - simplywall.st
Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Jazz Pharmaceuticals stock hits all-time high at 261.46 USD By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $285, Implies 13% Upside - TradingView
Jazz Pharmaceuticals plc Q2 2026 Earnings Call Summary - Yahoo Finance
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results - Benzinga
What Jazz Pharmaceuticals’ Q2 Earnings Call Revealed About the Zanidatamab Bet - TIKR.com
JAZZ PHARMACEUTICALS PLC : RBC RAISES TARGET PRICE TO $273 FROM $258 - Bitget
Earnings call transcript: Jazz Pharmaceuticals raises 2026 outlook after Q2 miss - Investing.com
Jazz Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Jazz Pharmaceuticals PLC (J7Z.SG) Q2 FY2026 earnings call transcript - Yahoo Finance
Jazz Pharmaceuticals plc Q2 2026: Revenue $1156.1M, EPS $2.78— 10-Q Summary - TradingView
Bruce Cozadd plans 6,000-share Jazz Pharmaceuticals (JAZZ) stock sale after prior sales - Stock Titan
Jazz Pharmaceuticals posts record $1.21B Q2 revenue, raises 2026 guidance - TradingView
JAZZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jazz Pharmaceuticals (JAZZ) swings to H1 2026 profit and trims $1B in debt - Stock Titan
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Reports Q2 Revenue $1.21B, vs. FactSet Est of $1.11B - marketscreener.com
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q2 Adjusted EPS $5.71 per Share - marketscreener.com
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results - TradingView
Jazz Pharma in the spotlight: Can earnings momentum continue? - Investing.com
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and Promising Growth Potential - DirectorsTalk Interviews
0.52%
0.07%
자본화:
|
볼륨(24시간):